Billy Evans, the husband of Elizabeth Holmes — the founder of the now-defunct blood testing company Theranos — is developing a new startup aimed at ‘human health optimization’ through blood diagnostics. Although details remain scarce, early reports suggest that the venture seeks to harness blood data to offer insights into individual health and wellness.
Evans, who has remained mostly out of the public eye since Holmes’ high-profile federal fraud conviction in 2022, appears to be stepping into the biotech and wellness sector with a new vision. Unlike Theranos, which infamously promised to run hundreds of tests using only a few drops of blood — a claim that ultimately led to the downfall of the company and Holmes’ imprisonment — this new company reportedly focuses more realistically on personal health tracking.
According to initial disclosures, the startup aims to help users optimize their health by tracking biomarkers present in blood samples. These could include indicators of inflammation, vitamin and hormone levels, or other physiological metrics that offer insights into how the body is performing.
It is not yet clear what level of clinical support or regulatory oversight Evans’ new venture will pursue, but the legacy of Theranos poses a challenging backdrop. Theranos was once valued at $9 billion before being dismantled following revelations that its technology did not work as claimed, and that it misled investors, patients, and regulators. Holmes was convicted of multiple counts of wire fraud and is currently serving an 11-year sentence.
Evans reportedly married Holmes in 2019 and the couple have since had two children. During and following Holmes’ trial, Evans has largely remained silent in public forums, but this new health-centric initiative places him back into the Silicon Valley startup ecosystem.
The company has not yet been named, and no launch date, funding details, or scientific advisors have been officially confirmed. However, the prospect of another wellness startup emerging from Holmes’ inner circle is likely to draw both interest and scrutiny.
As the new venture develops, Evans will likely face questions about how his company intends to differentiate itself in the marketplace, which already includes popular consumer health platforms like Levels, InsideTracker, and Thorne. The credibility and transparency of scientific claims will also be under close watch, given the Theranos precedent.
The startup’s approach to blood metrics could align with a growing sector of personalized health, where individuals monitor and adjust lifestyle, diet, and supplements based on real biological data. Whether Evans’ venture can gain trust and succeed where Theranos failed remains to be seen.
Source: https:// – Courtesy of the original publisher.
